Chairs:
Thomas Lynch, Jr, MD Yale School of Medicine New Haven, CT, United States		Alberto Sobrero, MD                 San Martino Hospital Genova, Italy
Faculty:
David Ryan, MD                     Massachusetts General Hospital                Boston, MA, United States		Robert Pirker, MD Medical University of Vienna Vienna, Austria

6:00 PM		Registration & dinner
6:30 PM		Is individualized therapy for common solid tumors ready for prime time? Thomas Lynch, Jr, MD
6:45 PM		Pattern of practice question: Targeting EGFR in metastatic colorectal cancer
6:50 PM		How should we integrate EGFR inhibitors into first-line therapy for metastatic colorectal cancer? David Ryan, MD
7:10 PM		Interactive clinical case: Metastatic colorectal cancer Alberto Sobrero, MD
7:30 PM		Pattern of practice question: Targeting EGFR in NSCLC
7:35 PM		Contemporary strategies for incorporating anti-EGFR therapies in advanced NSCLC    Robert Pirker, MD
7:55 PM		Interactive clinical case: Advanced NSCLC Thomas Lynch, Jr, MD
8:15 PM		Individualized therapy:  Where do we go from here? Alberto Sobrero, MD
8:30 PM		Adjourn

Upon successful completion of this educational activity, attendees should be able to:

• Identify potential methods for predicting clinical response to EGFR targeted agents in colorectal cancer and non-small cell lung cancer (NSCLC)
• Review recent clinical data regarding the use of EGFR antibodies as first-line therapy for metastatic colorectal cancer and advanced NSCLC
• Identify the potential role of combining radiation with EGFR inhibitors in the management of advanced NSCLC
• Define strategies for the integration of EGFR inhibitors into clinical practice
• Describe markers that may allow oncologists to individualized therapy for metastatic colorectal cancer and advanced NSCLC

Both lung cancer and colorectal cancer have a large impact, with 215,020 new cases of lung cancer and 161,840 deaths estimated in 2008, and an estimated 148,810 new cases and 49,960 deaths from colorectal cancer in 2008. Despite the many advances made in the fields of non-small cell lung cancer (NSCLC) and colorectal cancer, current treatment options are mostly unsuccessful for patients who relapse after initial treatment. 
 
The fields of NSCLC and colorectal cancer are constantly being updated, especially with regard to the optimal application of EGFR inhibitors, and oncologists in both academic and community practice settings need easily accessible, one-stop resources where they can review and validate current standards and practice guidelines in order to optimize and individualize patient care. PRIME Oncology will meet this educational need through a satellite symposium titled Individualizing Targeted Therapy for Lung and Colorectal Cancers. The symposium will provide expert analysis of optimal approaches to integrating EGFR inhibitors into clinical practice. 

Postgraduate Institute for Medicine and PRIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM and PRIME Oncology for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and PRIME Oncology. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.